A CRISPR-Cas13a Based Strategy That Tracks and Degrades Toxic RNA in Myotonic Dystrophy Type 1

A CRISPR-Cas13a Based Strategy That Tracks and Degrades Toxic RNA in Myotonic Dystrophy Type 1

Cas13a, an effector of type VI CRISPR-Cas systems, is an RNA guided RNase with multiplexing and therapeutic potential. This study employs the Leptotrichia shahii (Lsh) Cas13a and a repeat-based CRISPR RNA (crRNA) to track and eliminate toxic RNA aggregates in myotonic dystrophy type 1 (DM1) – a neur...

Full description

Bibliographic Details
Main Authors: Nan Zhang, Brittani Bewick, Guangbin Xia, Denis Furling, Tetsuo Ashizawa
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-12-01
Series:Frontiers in Genetics
Subjects:
myotonic dystrophy
neurodegeneration
CRISPR-Cas13a
RNA targeting
stress granule
Online Access:https://www.frontiersin.org/articles/10.3389/fgene.2020.594576/full

Internet

https://www.frontiersin.org/articles/10.3389/fgene.2020.594576/full

Similar Items